Physician profile
Kristina E Ray
NPI 1598831422
$3,598.66
in general payments reported to CMS, 2019-2025
26 companies · $50.37 in 2025
The $50.37 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $139 · 2020: $690 · 2021: $965 · 2022: $725 · 2023: $742 · 2024: $289 · 2025: $50.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.12 | 2021-2025 | |
| Allergan, INC. | $346.07 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.29 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $226.95 | 2019-2024 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $223.78 | 2019-2024 | Farxiga, Airsupra |
| Organogenesis INC. | $204.68 | 2020-2021 | |
| Novo Nordisk INC | $191.89 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $191.34 | 2019-2023 | Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $156.96 | 2021-2022 | |
| Pfizer INC. | $138.96 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $96.39 | 2023-2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $87.19 | 2020-2022 | |
| Axsome Therapeutics, INC. | $77.44 | 2023-2024 | Auvelity |
| Glaxosmithkline, LLC. | $61.25 | 2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $59.34 | 2020-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.00 | 2020 | |
| Eisai INC. | $52.45 | 2020-2021 | |
| Amarin Pharma, INC. | $47.36 | 2020-2021 | |
| Exact Sciences Corporation | $43.62 | 2023 | Cologuard Collection Kit |
| Amgen INC. | $31.61 | 2022 | |
| Phathom Pharmaceuticals, INC. | $30.12 | 2024 | Voquezna |
| Currax Pharmaceuticals LLC | $29.10 | 2020 | |
| Merck Sharp & Dohme LLC | $23.10 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.41 | 2025 | Caplyta |
| Genentech USA, INC. | $14.05 | 2021 | |
| Mylan Specialty L.P. | $13.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristina Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.